(TXMD) TherapeuticsMD, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TXMD) TherapeuticsMD, Inc. Complete Analysis Pack
See the Bigger Picture
This TherapeuticsMD, Inc. BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation analysis. The page already shows a real preview of the actual report content, so you can review what you’ll get before purchasing. Buy the full version to unlock the complete ready-to-use analysis.
Stars
BIJUVA, 1 mg estradiol/100 mg progesterone
BIJUVA is TherapeuticsMD, Inc.'s lead oral menopause therapy and its clearest Star asset, with the best growth runway in the branded Rx portfolio. The market is large and recurring: about 1.3 million U.S. women enter menopause each year, and roughly 50 million are menopausal today. Continued promotion and broader access can still lift share in this durable category.
IMVEXXY, 4 mcg and 10 mcg vaginal inserts
IMVEXXY, available in 4 mcg and 10 mcg, targets moderate to severe dyspareunia from vulvar and vaginal atrophy, a persistent menopause-care need. It is one of TherapeuticsMD, Inc.’s key branded assets, and share gains hinge on physician awareness and pharmacy placement. The 2-dose format supports expansion in a clinically durable market.
Women’s health Rx franchise, 3 marketed brands
In FY2025, TherapeuticsMD’s commercial mix stayed concentrated in just 3 marketed Rx brands, so this women’s health franchise carries most of the company’s growth upside. It sells into a specialty care niche, not mass-market demand, which can support pricing power but limits scale outside the core.
U.S. wholesale and retail pharmacy channels
TherapeuticsMD, Inc. uses U.S. wholesale and retail pharmacy channels, so branded prescriptions can move through standard reimbursement and repeat-fill paths. In a small pharma model, access and placement can matter as much as the product, because pharmacy reach can drive script volume and refill persistence.
Channel strength is a clear Star lever if formulary access stays broad and stocking is steady. The key watchpoint is simple: if pharmacies can fill, reimburse, and repeat dispense without friction, volume can scale faster than a limited sales force can push it.
- Wholesale and retail pharmacies support reimbursement.
- Repeat dispensing can lift branded script volume.
- Access and placement drive growth.
- Channel reach can rival product strength.
Menopause and genitourinary syndrome of menopause markets
Menopause and genitourinary syndrome of menopause are large, age-linked markets with steady use because symptoms are chronic and often untreated. In the U.S., about 6,000 women reach menopause each day, and the 50+ female cohort keeps growing, so demand should stay durable. TherapeuticsMD’s Rx brands sit in this core niche, making it the best long-term growth area if share expands.
Large, recurring demand base.
Aging female population supports growth.
Best fit for share gains.
BIJUVA and IMVEXXY Drive TherapeuticsMD’s Growth Upside
BIJUVA and IMVEXXY are TherapeuticsMD, Inc.'s Stars because they sit in large, chronic menopause markets and still have room to gain share. In FY2025, the franchise stayed concentrated in 3 branded Rx products, so these therapies drive most growth upside. Broad pharmacy access and repeat fills are the main volume levers.
| Asset | Star role | Market note |
|---|---|---|
| BIJUVA | Lead Star | 1.3M U.S. women enter menopause yearly |
| IMVEXXY | Key Star | 50M menopausal women in U.S. |
What is included in the product
Detailed Word Document
TherapeuticsMD’s BCG Matrix maps its women’s health portfolio to show where to invest, hold, or divest amid shifting market demand.
Editable Excel File
Quick BCG snapshot of TherapeuticsMD, Inc. to pinpoint each unit’s position and simplify strategy decisions
Reference Sources
Provides a credible source trail for TherapeuticsMD, Inc. to verify key claims fast and support confident decisions.
Cash Cows
vitaTrue, prenatal vitamin line
vitaTrue is a recurring prescription nutrition line, so it fits the Cash Cow box. Prenatal vitamins sit in a mature, refill-driven category; demand is steady because patients often need a daily 30-day supply through pregnancy and postpartum. Growth is usually modest, but lower launch and promotion costs can still support stable cash generation.
vitaPearl, prenatal vitamin line
vitaPearl sits in a stable women’s health nutrition niche where demand is recurring, not hype-driven. Prenatal use is tied to a roughly 9-month pregnancy cycle, so mature brands can keep sales coming with limited promo spend. That steady, low-growth profile fits the BCG cash cow bucket and can help fund TherapeuticsMD, Inc.’s other priorities.
vitaMedMD, prenatal vitamin line
vitaMedMD is another branded prenatal vitamin in TherapeuticsMD, Inc.’s nutrition portfolio, with demand that is stable rather than fast-growing. In a crowded prenatal vitamin market, cash flow comes more from shelf access, reorder rates, and distribution efficiency than from big volume jumps. That makes it a low-growth, steady-revenue cash cow.
BocaGreenMD Prena1, prenatal vitamin line
BocaGreenMD Prena1 fits the Cash Cows box because prenatal vitamins sit in a mature, replenishment-led market where demand is routine, not innovation-driven. TherapeuticsMD reported $0 revenue in 2025 and $0 in Q1 2026, so any cash contribution from this line depends on keeping pharmacy and channel access in place.
- Routine prenatal use supports repeat sales.
- Mature category means low innovation needs.
- Channel presence is the key value driver.
- 2025 and Q1 2026 revenue were $0.
Branded and generic prescription prenatal vitamins
Branded and generic prescription prenatal vitamins are TherapeuticsMD, Inc.’s most mature cash cow: demand is recurring, refill-driven, and far less volatile than branded Rx launches. The segment can be kept alive with low promotional spend, so it throws off steady cash rather than growth. In BCG terms, that makes it the clearest funding base for newer bets.
Most mature portfolio line
Recurring prescription demand
Low promo intensity needed
Reliable cash generation
Mature Prenatal Brands: Stable Cash Base, Zero Reported Revenue
TherapeuticsMD, Inc.'s cash cows are its mature prenatal vitamin brands, where demand is repeat-based and promotion needs are low. In 2025 and Q1 2026, reported revenue was $0, so the cash value here depends on preserving channel access and refill flow, not growth. That makes this the portfolio’s most stable funding base.
| Metric | Value |
|---|---|
| 2025 revenue | $0 |
| Q1 2026 revenue | $0 |
| Market type | Mature, refill-led |
What You See Is What You Get
TherapeuticsMD, Inc. Reference Sources
You’re previewing the exact TherapeuticsMD, Inc. BCG Matrix document that will be delivered after purchase. The full file comes with the same structure, formatting, and content—no placeholders, no demo version. Buy once, and you’ll receive the ready-to-use report instantly for review, editing, or presentation.
Dogs
ANNOVERA, 1-year contraceptive vaginal ring
ANNOvera is a 1-year contraceptive vaginal ring in a crowded, low-growth market where oral pills, IUDs, implants, and other rings already dominate. Its share has stayed limited, so it fits the BCG "Dog" profile: weak relative position in a mature category. If traction does not improve, TherapeuticsMD, Inc. faces continued pressure because the product has not shown scale against longer-acting options.
Contraception segment, low-share niche
TherapeuticsMD, Inc.’s contraception unit sits in a mature, crowded market where incumbents already dominate and new-product uptake is slow. For a small company, that usually means weak share, thin scale, and poor pricing power. Unless it wins rapid traction, this line behaves like a "Dog" in the BCG Matrix.
Single-brand dependence in contraception
ANNOVERA is TherapeuticsMD, Inc.'s only branded contraception asset, so the company is exposed to one product line and one launch cycle. In a mature U.S. contraception market serving tens of millions of women, weak volume quickly pressures unit economics and limits scale. That concentration makes execution risk high, and if demand stalls, ANNOVERA fits classic dog behavior.
Limited commercial scale
TherapeuticsMD fits the Dogs box because its commercial base is thin: after divestitures, it no longer has the broad women’s-health lineup that larger peers use to spread selling, G&A, and support costs. With little or no revenue scale in 2025/2026, fixed costs hit returns harder, and weak share leaves limited leverage in marketing and distribution.
- Small portfolio, weak scale
- Fixed costs weigh on returns
- Low share, low-growth profile
Legacy commercialization burden
TherapeuticsMD’s legacy commercialization burden fits the dog quadrant because supporting niche products with tight resources can add cost without building share. After the women’s health asset sale, the business had little or no commercial scale left to absorb selling, marketing, and admin costs. In BCG terms, that means weak return on effort and low strategic value if the brand cannot win share fast.
- High cost, low momentum
- Weak sales force return
- No fast share gain
- Stay close to "dog"
ANNOVERA: A Dog in a Mature Market
ANNOVERA remains a Dog: a niche 1-year ring in a mature U.S. contraception market, while TherapeuticsMD, Inc. had little commercial scale in 2025/2026 after its women’s-health asset sale. With weak share and thin revenue leverage, fixed selling and G&A costs still press returns. One product, little growth, low strategic upside.
| Item | 2025/2026 |
|---|---|
| Commercial scale | Minimal |
| Portfolio | 1 core brand |
| Market type | Mature, low-growth |
| BCG fit | Dog |
Question Marks
TX-005HR, progesterone transdermal cream
TX-005HR is a preclinical progesterone transdermal cream, so it has no current market share or revenue contribution for TherapeuticsMD. It targets women’s hormone therapy, where demand is real, but clinical failure and FDA risk remain high, so the upside is still unproven. That profile fits a textbook question mark: high potential, low traction, and capital needs before any scale.
TX-006HR, estradiol-plus-progesterone cream
TX-006HR, TherapeuticsMD, Inc.’s estradiol-plus-progesterone cream, is still in development and has no reported revenue or market share yet. That puts it in the Question Marks box: the product could fit menopause care if clinical and commercial execution land well, but it has not proven demand. Until it shows real sales traction, it remains a high-potential, high-risk bet.
TX-007HR, transdermal patch
TX-007HR, the transdermal patch, has no disclosed commercial position today, so its BCG spot is a question mark. Transdermal delivery can support better convenience and adherence, but the asset still faces high development risk and unclear approval timing. With no reported sales base, it remains a high-potential, low-share program for TherapeuticsMD, Inc.
TX-008HR, transdermal patch
TX-008HR has no market share today, so it fits the BCG "question mark" bucket. TherapeuticsMD, Inc. still needs proof that this transdermal hormone patch can win on safety, efficacy, and patient fit before it can turn into a growth asset.
Patch-based hormone drugs can appeal because they avoid daily pills and may improve dosing convenience and preference, but that alone does not create demand. In 2025, TX-008HR was still a development-stage candidate, with no disclosed sales or market share.
So the core question is not just clinical success, but whether the product can earn a place in a crowded hormone therapy market. Until the data are strong enough, TX-008HR stays a question mark.
- No market share yet
- Convenience can aid adoption
- Safety and efficacy come first
- Still a question mark
TX-009HR, oral progesterone-plus-estradiol
TX-009HR is still preclinical, so TherapeuticsMD, Inc. has no sales or market share yet. In a menopause market serving tens of millions of women in the U.S. alone, an oral progesterone-plus-estradiol pill could still scale if it reaches the clinic and proves safe and effective. For now, it is pure upside with zero current cash flow, which fits the BCG Question Mark label.
- Preclinical only; no revenue yet
- High market potential, no share
- Clear Question Mark in BCG terms
TherapeuticsMD’s Question Marks: High Upside, High Risk
TherapeuticsMD, Inc.’s Question Marks are TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR: all are still preclinical or development-stage, with no reported 2025 revenue or market share. That gives them upside in women’s hormone therapy, but also FDA, safety, and execution risk. Until any one shows real sales traction, they stay high-potential, low-share bets.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.